Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Aaron Everitt is a principal in the Life Sciences Practice of CRA. He has over five years of consulting experience in Pricing & Market Access, across the EU and US, with experience in LATAM, APAC and MEA. Dr. Everitt has a PhD background in immunology and virology.